drugset / Trial / NCT05783609
Epcoritamab and Rituximab for First-line Follicular Lymphoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not received other treatments for their lymphoma. The names of the study drugs involved in this study are: * Rituximab (a type of monoclonal antibody therapy) * Epcoritamab (a T-cell bispecific antibody)
Timeline
- Start
- 2023-06-21
- Primary completion
- 2028-02
- Completion
- 2030-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epcoritamab | Monoclonal antibody | — | Subcutaneous |
| Subject | Rituximab | Monoclonal antibody | — | Intravenous |